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Prognosis of Stage II Colon Cancer by
Non-Neoplastic Mucosa Gene Expresssion
Profiling
Alain Barrier, Sandrine Dudoit, and et al.

Abstract

Aims. This study assessed the possibility to build a prognosis predictor, based
on non-neoplastic mucosa microarray gene expression measures, in stage II colon
cancer patients. Materials and Methods. Non-neoplastic colonic mucosa mRNA
samples from 24 patients (10 with a metachronous metastasis, 14 with no recurrence) were profiled using the Affymetrix HGU133A GeneChip. The k-nearest
neighbor method was used for prognosis prediction using microarray gene expression measures. Leave-one-out cross-validation was used to select the number
of neighbors and number of informative genes to include in the predictor. Based
on this information, a prognosis predictor was proposed and its accuracy estimated
by double cross-validation. Results. In leave-one-out cross-validation, the lowest
number of informative genes giving the lowest number of false predictions (3 out
of 24) was 65. A 65-gene prognosis predictor was then built, with an estimated
accuracy of 79%. Genes included in this predictor suggested branching signal
transduction pathways with possible extensive networks between individual pathways. It also included genes coding for proteins involved in immune surveillance.
Conclusion. This study suggests that one can build an accurate prognosis predictor for stage II colon cancer patients, based on non-neoplastic mucosa microarray
gene expression measures.

Introduction

Despite numerous clinical trials, the benefit of adjuvant chemotherapy in the treatment
of stage II colon cancer patients has never been proved in a randomized study. In most metaanalyses, there is a trend towards a benefit of adjuvant chemotherapy, but statistical
significance is not reached [1]. Thus, this benefit seems to exist but, as it is slight, studies are
not powerful enough to demonstrate it. This ambiguous situation is perfectly summarized by
the conclusion of the 2004 recommendations of the American Society of Clinical Oncology
[2]: “Direct evidence from randomized controlled trials does not support the routine use of
adjuvant chemotherapy for patients with stage II colon cancer. Patients and oncologists … are
justified in considering the use of adjuvant chemotherapy, particularly for those patients with
high-risk stage II disease. … Patients with stage II disease should be encouraged to participate
in randomized trials”.
Including all stage II colon cancer patients in a randomized trial is debatable. Even if a
properly-designed study, comprising thousands of patients, demonstrated a statistically
significant benefit of adjuvant chemotherapy, it may not be logical to conclude that this
treatment should be given to all stage II patients. Such a conclusion would not take into
account that three fourths of the patients are cured by surgery alone and would lead to
administering to all patients a treatment that would be useful for only a few. Another more
rational approach would be to identify a subgroup of patients at high risk of recurrence, thus
more likely to benefit from adjuvant chemotherapy, and to include only these selected patients
in a randomized trial. This presupposes finding accurate prognosis predictors for stage II
colon cancer patients.
Microarray gene expression profiling has been reported to accurately predict the
prognosis of several malignant tumors (breast carcinomas [3,4], lung carcinomas [5,6],

Hosted by The Berkeley Electronic Press

lymphomas [7,8]). Thus, by analogy with these tumors, it may be postulated that gene
expression profiling represents a valuable tool in predicting the prognosis of stage II colon
cancer patients and thereby in identifying a subgroup of patients at high risk of recurrence. To
date, this hypothesis has only been addressed in the study of Wang et al. [9], with good results
(overall prediction accuracy of 78%).
The present study aimed to assess the possibility to build a microarray-based prognosis
predictor for stage II colon cancer patients using non-neoplastic mucosa gene expression
profiles. The rationale for studying the non-neoplastic mucosa, in contrast to tumor tissue as
in Wang et al [9], may be summarized as follows. There is an increasing evidence that
interactions between stromal and cancer cells are a prerequisite for metastases to occur [10].
However, it remains unclear whether this metastatic potential originates in cancer cells and/or
in stromal compartments. Metastatic potential may be present from the start of the tumor
[11,12]. Accepting this theory, non-neoplastic mucosa on which the tumor has arisen may
contain some helpful information. Non-neoplastic mucosa mRNA samples from 24 patients,
with homogeneous disease (stage II) and postoperative treatment (no adjuvant chemotherapy),
but different outcomes (10 with metastatic recurrence, 14 with no recurrence), were profiled
using the Affymetrix HGU133A GeneChip.
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Materials and Methods

Patients and samples

Twenty-four patients operated on for a stage II colonic adenocarcinoma in the Department of
Digestive Surgery of the Hospital Tenon between 1997 and 1999 were included in this study.
None of these 24 patients had any adjuvant chemotherapy. Patients were evaluated at 3-month
intervals for the first postoperative year and at 6-month intervals thereafter. Metastatic
reccurrences were identified by clinical examination, completed by chest X-ray and liver
ultrasound (or CT scan). Ten among the 24 patients developped a liver metastasis in the
follow-up, while the other 14 patients remained disease-free for at least 60 months.
For each patient, adjacent non-neoplastic colon mucosa (distance greater than 5 cm from the
gross tumor limit) was collected at the time of surgery, with patients’ informed consent, and
was stored in liquid nitrogen within 0.5 hour after the resection. Samples were reviewed by a
pathologist to check the absence of tumor cells.

Total RNA was extracted using Trizol reagent. mRNA target samples were hybridized to
Affymetrix HGU133A GeneChips, containing a total of 22,283 probe-sets (Affymetrix, Santa
Clara, CA), as described in the Affymetrix GeneChip Expression Analysis Manual
(Affymetrix, Wooburn Green, UK). Briefly, 5 µg (100 ng/µl) of total RNA was used to
synthesize double-stranded cDNA with SuperScript II reverse transcriptase (Invitrogen, Cergy
Pontoise, France) and a T7-(dT)24 primer (Proligo Biochemie GmbH, Hamburg, Germany).
Then, biotinylated cRNA was synthesized from the double-stranded cDNA using the RNA
Transcript Labeling kit (Enzo Life Sciences, Farmingdale, NY) and was purified and
fragmented. The fragmented cRNA was hybridized to the oligonucleotide microarray, which
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was washed and stained with streptavidin-phycoerythrin. Scanning was performed with a
GeneArray Scanner Update (Affymetrix, Wooburn Green, UK).

Data analysis

Data pre-processing
Starting from the 24 CEL files, gene expression measures were computed using the Robust
Multichip Average (RMA) method described in Irizarry et al. [13] and implemented in the
Bioconductor R package affy. This method includes the following successive steps : 1)
Background correction ; 2) Probe-level quantile normalization ; 3) Calculation of expression
measures using median polish.

Prognosis prediction
The prognosis prediction method consists of the following two steps.
a) Selection of informative genes. Genes that are differentially expressed between patients
who experienced a tumor relapse and patients who remained disease-free are identified based
on two-sample t-statistics with equal variance. The m genes with the largest absolute tstatistics are retained to build a prognosis predictor.
b) Prognosis prediction. The k-nearest neighbor method, based on the Euclidean distance
between the expression profiles for the m informative genes of step a), is applied to predict
prognosis. Specifically, the prognosis of a given patient is predicted as the most common
prognosis among its k nearest neighbors, i.e., the k patients with the closest expression
profiles.
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Selection of prognosis predictor parameters
Leave-one-out cross-validation was used to select the two prognosis predictor parameters,
namely the number of informative genes m and the number of nearest neighbors k. A total of
150 prognosis predictors were considered, corresponding to the following parameter values: k
= 1, 3, and 5, and m = 5, 10, …, 250. The performance of a given prognosis predictor,
indexed by the pair (m,k), was assessed as follows. Each of the 24 samples was used in turn as
the validation set; the prognosis predictor was built using the training set formed by the
remaining 23 samples and used to assign a prognosis (recurrence or no recurrence) to the
validation sample; the predicted prognosis was then compared to the actual recurrence status;
the numbers of false predictions (discordance between the predicted and actual evolutions)
and true predictions were recorded for each of the 24 samples. Thus, for each of the 150
prognosis predictors, i.e., each (m,k) pair, a prediction error rate (out of 24) was obtained.

Proposition of a prognosis predictor
Because of ties in the error rates from leave-one-out cross-validation, the number of
informative genes of this predictor was set to be the lowest number of informative genes,
giving the lowest number of false predictions. Selection of informative genes was based on
the 24 samples.

Estimation of the generalization error of the prognosis predictor
A double cross-validation scheme was used to assess the performance of the proposed
prognosis predictor. For the “outer level” of cross-validation, the 24 samples were divided
into 6 sets of 4 samples each (6-fold cross-validation). Each of these 6 sets was used in turn as
the validation set, the other 5 sets (20 patients) being used as the training set. For each of the 6
steps in the cross-validation, a prognosis predictor was built based on the training set using
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the method previously described: i) determination of the lowest number of genes and the
lowest number of nearest neighbors giving the lowest number of false predictions (out of 20),
using leave-one-out cross-validation (“inner level” of cross-validation); ii) selection of the m
informative genes based on the 20 patients. The predictor was used to assign a prognosis to
the 4 “outer level” validation set samples. The predicted prognoses were then compared to the
actual recurrence status, giving a false prediction rate (out of 4). The 6 false prediction rates
(one for each of the 6 steps of the outer level cross-validation) were averaged to provide an
estimate of the generalization error.

Software
The statiscal analysis was performed with the open-source software R, Version 2.0.1.
(http://cran.r-project/org), and Bioconductor packages (www.bioconductor.org). The
following R packages were used : affy Version 1.5.8. (Irizarry RA, Gautier L, Bolstad BM,
Miller C), multtest Version 1.5.2. (Pollard KS, Ge Y, Dudoit S), class Version 7.2.11.
(Venables T, Ripley B, Hornik K, Gebhardt A), hgu133a Version 1.6.5. (Zhang J), and
annaffy Version 1.0.11. (Smith CA).
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Results

Selection of prognosis predictor parameters
A total of 150 prognosis predictors (50 possible values for the number m of informative
genes, 3 possible values for the number k of nearest neighbors) were considered and their
performance assessed using leave-one-out cross-validation. The distribution of the numbers of
false predictions obtained with each of these 150 predictors is given in Figure 1. No pair of
parameters (m, k) allowed a perfect concordance between the predicted and the observed
evolutions. The numbers of false predictions ranged between 3 and 7. Three false predictions
(out of 24, accuracy = 88%) represented the best and most frequent result (96 out of 150) .
Figure 2 shows the numbers of false predictions obtained with respect to the values of both
parameters, m and k. Predictors built with 30 or fewer informative genes yielded the highest
numbers of false predictions (5 to 7). Predictors built with more than 60 informative genes
yielded stable results and low numbers of false predictions. For a given number of informative
genes, the results were quite similar for different numbers of nearest neighbors. The lowest
number of informative genes giving the lowest number of false predictions (=3) was 65.

Proposition of a prognosis predictor
Based on the results of the leave-one-out cross-validation, 65 informative genes were selected
using all 24 patients, by taking the 65 top-ranked genes (i.e., the 65 genes with the highest
absolute t-statistics). Of these genes, 44 were over-expressed in patients who developed a
recurrence while the other 21 were over-expressed in patients who remained disease-free for
at least 5 years. Both lists of genes are given in Tables 1 and 2, respectively. Informative
genes can be divided into 3 categories: 1) plasma membrane receptors with members of
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different signaling pathways and transcription factors, 2) proteins involved in cell growth
and/or maintenance such as glucose metabolism, protein biosynthesis, transport and
degradation, and 3) proteins involved in the immune response. The following membrane
receptors were over-expressed in the mucosa of patients who recurred: solute carrier family
18; translocation protein 1; annexin 2; exostoses 2; ribophorin II; transmembrane protein 4;
two

G

protein-coupled

receptors

involved

in

positive

regulation

of

I-kappaB

kinase/NFkappaB cascade; KDEL endoplasmic reticulum protein retention receptor 3 that can
modulate MAP kinase signalling; immediate early response 3 interacting protein 1; and
integral membrane protein 2A. Membrane receptors that were over-expressed in the mucosa
of patients who remained recurrence-free belong to different families, except for
transmembrane 4 superfamily member 2. There were : CD24 antigen, a protein involved in
the humoral immune response that is also a membrane receptor over-expressed on epithelial
cancer cells; signal transducer and activator of transcription 2 that induces the JAK-STAT
cascade; SPPL2b; potassium voltage channel shaker-related family beta member 1; basigin;
and major histocompatibility complex class I C. As most of the cell surface receptors are
linked to signal transduction, an over-expression of some signal transducers and factors of
transcription was also observed : WD40 protein ciao 1 that can interact with tumor suppressor
proteins, and ADP-ribosylation factor-like 1 in patients who recurred ; cyclin-dependent
kinase (CDC2-like) 10, ankyring repeat and SOCS-box containing 13 in patients who did not
recur. Among genes involved in immunity, two transcripts, CD24 and the major
histocompatibility complex class I, C were overexpressed in the mucosa of patients who did
not recur. Two members of the forkhead-box transcription factors, forhead boxO1A and
forkhead box J3, were overexpressed in patients who recurred and in those who did not recur,
respectively.
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Estimation of the generalization error of the prognosis predictor
The results obtained at each of the 6 steps of the “outer level” cross-validation are
summarized in Table 3. For each step, 20 samples were used as the training set, while the
other 4 were used as the validation set. The second column indicates the distribution of the
numbers of false predictions obtained with each of the 150 predictors in the “inner level”
cross-validation based on the 20 patients of the training set. The third column gives the lowest
numbers of informative genes and nearest neighbors that yielded the lowest number of false
predictions for “inner level” leave-one-out cross-validation. These parameter values were
used to build the prognosis predictor based on the training set of size 20. This predictor was
applied to assign a prognosis to each of the 4 patients of the validation set. The false
prediction rates, obtained for each of the 6 steps, are given in the fourth column. The average
of these 6 false prediction rates (21%) provides an estimate of the accuracy of our proposed
prognosis predictor (79%).
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Discussion

The results of the present study clearly suggest the possibility to build a prognosis
predictor based on non-neoplastic mucosa gene expression profiles for stage II colon cancer
patients. To our knowledge, this is the first time that such a conclusion is reported. Wang et
al. [9] have proposed an accurate prognosis predictor for stage II colon cancer patients, but
based on tumor gene expression profiles. Non-neoplastic colonic mucosa profiles have
already been studied, but only to compare them to tumor profiles [14-17].

Studies aiming to propose a predictor, for either diagnosis or prognosis purposes, are
usually designed as follows: samples are split into a training set and a validation set;
informative genes are selected based on the training set, using some arbitratory rule; the
resulting predictor is assessed on the validation set. The design of the present study, which
includes two distinct rounds of cross-validation with different aims, needs to be explained.
The first part concerns the selection of a predictor using cross-validation, while the second
aims to estimate the generalization error of the selected predictor. The k-nearest neighbor
classifier was chosen because it has been shown to be competitive with more complex
approaches, such as aggregated classification trees and support vector machines [18,19]. The
main parameters of this classifier, namely the numbers of informative genes m and nearest
neighbors k, were not chosen a-priori but using cross-validation in the first part of the study.
Specifically, 150 different pairs of parameters were considered and the performance of
each was assessed using leave-one out cross-validation. Even this first part mainly aimed to
select the predictor parameters, it also allowed to draw some informations about the stability
of non-neoplastic mucosa-based prognosis predictors, i.e., the sensitivity of prediction error to
the parameters (m, k). With a few informative genes (50 and less), predictor performance was
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inversely proportional to the number of genes. With more informative genes, the prediction
error rate seemed to stabilise.
Based on results of the first part, a 65-gene prognosis predictor was built on the whole
set of patients. When proposing a predictor, it is important to provide an estimate of its
accuracy. As a second set of independent samples was not available, a double cross-validation
design was used with an “inner level” leave-one-out cross-validation, for parameter selection,
and an “outer level” 6-fold cross-validation, for performance assessment of the selected
predictor. In order to obtain an honnest estimate of generalization error, it is crucial that all
aspects of predictor selection be included in the cross-validation process. Thus, for each of the
6 steps of the “outer level” cross-validation, we reproduced exactly what had been done in the
first part of the study with an “inner level” cross-validation: i) selection of the parameters (m,
k) yielding the best results by leave-one-out cross-validation, ii) use of this information to
build a predictor based on the 20 patients. Note that the estimate of the generalization error,
obtained by averaging the estimates of the “outer level” cross-validation, should be
conservative, since it is computed based on sets of 20 patients (instead of 24). Thus, one may
be confident that the accuracy of the proposed predictor is not over-estimated.

Wang et al. [9] reported a 78% accuracy in predicting the prognosis of stage II colon
cancer patients with a predictor based on tumor gene expression profiles, while our predictor,
based on non-neoplastic mucosa gene expression profiles, yielded a similar estimated
accuracy (79%). The question of whether one should build a prognosis predictor based on
tumor or non-neoplastic mucosa gene expression profiles immediately arises. In the present
study, the paired tumor samples were not profiled since the aim was not to compare both
predictors but to assess non-neoplastic mucosa-based predictors. However, in future studies, it
would be of interest to compare the performances of both kinds of predictors. From a practical
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point of view, the non-neoplastic mucosa represents an homogeneous pathological sample,
while the tumor includes both tumoral and non-tumoral cells. The use of non-neoplastic may
though avoid the need of laser-capture microdissection.
Despite the major difference in tissue material, the present study and that of Wang et
al. [9] share an important conclusion: gene expression profiling is able to predict, with a great
accuracy, the long-term postoperative outcome of stage II colon cancer patients. Thus, by
identifying a subgroup of patients at high risk of recurrence, gene expression profiling may be
used for postoperative therapeutical indications. To date, there is not enough evidence to
claim that adjuvant chemotherapy should be given or not, based on gene expression profiles.
But, initially, these profiles may be helpful for clinical studies assessing chemotherapy in
stage II colon cancer patients: instead of including all these patients, these studies may be
designed to include only patients identified as having a high risk of recurrence, thus more
likely to benefit from adjuvant chemotherapy.

Interestingly, genes included in the proposed predictor are not cancer genes or genes
encoding elements of the adhesion system, migration or proteolysis, but rather suggest
branching signal transduction pathways with possible extensive networks between individual
pathways and between cells themselves. For example, in the non-neoplastic mucosa of
patients who recurred, we have observed an over-expression of two membrane receptors,
annexin 2, and transmembrane protein 4, previously shown to be involved in tumor invasion
[20-22]. Conversely, in the mucosa of patients who did not recur after a follow-up of 5 years,
we have observed an increased expression of some genes already reported to induce tumor
cell invasion: basigin, known to stimulate production of matrix metalloproteinases by
fibroblasts [23,24]; a member of transmembrane protein 4 [21,22]; and CD24 [25]. CD24 is a
mucin-like cell surface molecule on human neutrophils, pre-lymphocytes, and many epithelial
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tumors. Its over-expression in some epithelial tumors, frequently associated with a high tumor
grade, has suggested its prognostic value as a routine marker [25]. However, an absence of
expression of CD24 mRNA has also been observed in invasive mammary carcinoma derived
cells compared to non invasive cells [26]. The role of CD24 in the dissemination of tumor
cells could be due to different pathophysiological processes according to its cellular
localization. Indeed, it has been described to facilitate the interactions with P-selectin in
platelets or endothelial cells [27,28] and to regulate T-cell proliferation in lymphopenic host
[29]. Recently, the role of CD24 signaling in the mitochondrial regulation of apoptosis has
also been shown [30].
The over-expression of CD24 in the mucosa of patients who remained disease-free
was associated with over-expressions of the major histocompatibility complex and a member
of the forkhead box, a family of transcription factors recently shown to play a crucial role in
the immune system [31]. Emerging evidences suggest that epigenetic events associated with
tumor development and progression, such as deregulated methylation of CpG dinucleotides
and aberrant histone acetylation, may impair the immunogenic potential of cancer cells. A
central question in cancer immunology remains how the additional genetic alterations, both in
primary tumor and in the stromal cells, and the inherent proinflammatory processes can
activate tumoral immunity and thus induce immune tolerance. Thus, although the role of the
abnormal expression of these genes was not clearly defined as pro- or anti-invasive, our
results emphasize that the immune response, to promote the survival or the death of malignant
cells, is not restricted to immune cells that infiltrate tumors. The recruitment of cells distant
from the primary tumor could constitute a possible mechanism for the presence of lymphnode metastases in some solid tumors such as colorectal cancers.
The over-expression of genes coding for membrane receptors coupled with signal
transduction, such as G protein-coupled-receptor and protein kinases, transcription factors and
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members of cellular proteolysis systems, such as the Cop9 signalosome and 26S proteasome,
suggests an important cross talk between cells, probably connecting the initial events, e.g.
activation of receptors, to the activation of gene expression in the nucleus. The activation of
signalling pathways has been already shown to play a central function in invasion–related
cellular activities determining the cells response to extrinsic or intrinsic modulators [32].

In conclusion, the present study clearly suggests the possibility to build a prognosis
predictor, based on non-neoplastic mucosa gene expression profiles for stage II colon cancer
patients. It also raises questions regarding the role of the so-called “normal mucosa”
surrounding the tumor. Genomic alterations in epithelial cells which lead to primary tumors
may disturb the molecular cross-talk between cancer cells and the underlying stroma. This
conversation may be relayed by other host cells distant from the primary tumors, these cells
presenting normal phenotype and thus allowing an adaptated signalling. Several questions
remain to be elucidated. One of these is to determine whether normal cells distant from the
tumors are contacted to stop and repair or to help the cancer cell invasion.
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Table 1. Over-expressed genes in patients who developped a recurrence
Affy probeID

Gene Name

207074_s_at
213800_at
208942_s_at
202141_s_at

Solute carrier family 18 (vesicular monoamine), member 1
complement factor H
translocation protein 1
COP9 constitutive photomorphogenic homolog subunit 8
(Arabidopsis)
Sciellin
nuclear phosphoprotein similar to S. cerevisiae PWP1
annexin A2
WD40 protein Ciao1
tripartite motif-containing 2
pyruvate dehydrogenase (lipoamide) beta
exostoses (multiple) 2
annexin A2
polymerase (DNA-directed), delta 3, accessory subunit
nudE nuclear distribution gene E homolog like 1 (A.
nidulans)
proteasome (prosome, macropain) 26S subunit, ATPase, 2
annexin A2
ribophorin II
DnaJ (Hsp40) homolog, subfamily C, member 12

206884_s_at
201606_s_at
213503_x_at
203536_s_at
202341_s_at
211023_at
202013_s_at
210427_x_at
212836_at
208093_s_at
201067_at
201590_x_at
213399_x_at
218976_at
201543_s_at
202857_at
202723_s_at
209045_at
220841_s_at
218135_at
214307_at
207651_at
204017_at
211406_at
218257_s_at
219553_at
212342_at
222122_s_at
221766_s_at
201658_at
217868_s_at
201077_s_at
205141_at
205342_s_at
216228_s_at
222140_s_at
208095_s_at
213491_x_at
202747_s_at
201822_at

GenBank
Accession Number
NM_003053
X04697
BE866511
BC003090
NM_003843
BE796924
BE908217
NM_004804
AA149745
AL117618
NM_000401
BC001388
D26018
NM_030808

transmembrane protein 4
forkhead box O1A (rhabdomyosarcoma)
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble
Abelson helper integration site
PTX1 protein
homogentisate 1,2-dioxygenase (homogentisate oxidase)
G protein-coupled receptor 171
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein
retention receptor 3
immediate early response 3 interacting protein 1
UDP-glucose ceramide glucosyltransferase-like 1
non-metastatic cells 7, protein expressed in (nucleosidediphosphate kinase)
hypothetical protein MGC21416
THO complex 2
family with sequence similarity 46, member A
ADP-ribosylation factor-like 1
DORA reverse strand protein 1
NHP2 non-histone chromosome protein 2-like 1 (S.
cerevisiae)
angiogenin, ribonuclease, RNase A family, 5
sulfotransferase family, cytosolic, 1C, member 1
WD repeat and HMG-box DNA binding protein 1
G protein-coupled receptor 89
signal recognition particle 72kDa
ribophorin II
integral membrane protein 2A
translocase of inner mitochondrial membrane 17 homolog A
(yeast)

BF215487
NM_004039
AI560720
NM_021800
NM_020150
NM_014255
AW117498
AF195530
NM_017651
NM_016570
AI478172
NM_013308
NM_006855
AF119875
NM_020120
NM_013330
BG500611
BG403671
AW246673
AU151560
NM_016025
AF155235
NM_001145
AF026303
AK001538
AK021758
NM_001222
AL514285
NM_004867
NM_006335
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Table 2. Over-expressed genes in patients who remained disease-free

Affy probeID
209771_x_at
205170_at
215833_s_at
216379_x_at
210622_x_at
208651_x_at
266_s_at
207980_s_at
202242_at
200661_at
213827_at
208156_x_at
210079_x_at
211065_x_at
209357_at
216103_at
218862_at
208677_s_at
211799_x_at
200646_s_at
217310_s_at

Gene Name

GenBank
Accession Number
CD24 antigen (small cell lung carcinoma cluster 4 antigen) AA761181
signal transducer and activator of transcription 2, 113kDa
NM_005419
SPPL2b
AC004410
KIAA1919
AK000168
cyclin-dependent kinase (CDC2-like) 10
AF153430
CD24 antigen (small cell lung carcinoma cluster 4 antigen) M58664
CD24 antigen (small cell lung carcinoma cluster 4 antigen) L33930
Cbp/p300-interacting transactivator, with Glu/Asp-rich
NM_006079
carboxy-terminal domain, 2
transmembrane 4 superfamily member 2
NM_004615
protective protein for beta-galactosidase (galactosialidosis) NM_000308
sorting nexin 26
AL137579
epiplakin 1
NM_031308
potassium voltage-gated channel, shaker-related
U16953
subfamily, beta member 1
phosphofructokinase, liver
BC006422
Cbp/p300-interacting transactivator, with Glu/Asp-rich
AF109161
carboxy-terminal domain, 2
thioesterase, adipose associated
AB014607
ankyrin repeat and SOCS box-containing 13
NM_024701
basigin (OK blood group)
AL550657
major histocompatibility complex, class I, C
U62824
nucleobindin 1
NM_006184
forkhead box J3
AK027075
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m=40 , k=1

m=20 , k=3

m=105 , k=1

m=70 , k=1

m=10 , k=1

m=15 , k=3

(m, k)

Number of predictors with

3 FP *

Parameters

Leave-one-out cross-validation

Table 3. Results of the double cross-validation.

1/4 (25%)

0/4 (0%)

1/4 (25%)
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1/4 (25%)

2/4 (50%)
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FP Rate

Figure 1. Distribution of the numbers of false predictions.

A total of 150 prognosis predictors - 50 possible values for the number m of informative
genes (m = 5, 10, …, 250), 3 possible values for the number k of nearest neighbors (k = 1, 3,
and 5) - were considered and their performance assessed using leave-one-out cross-validation.
Figure 1 shows the distribution of the numbers of false predictions (out of 24) obtained with
each of these 150 predictors.
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Figure 2. Number of false predictions.

Figure 2 shows the number of false predictions as a function of the number m of informative
genes (x-axis) and the number k of nearest neighbors (y-axis). In these pseudo-color images,
colored rectangles indicate the number of false predictions, with yellow (black) corresponding
to the lowest (highest) numbers of errors.
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